Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214440 | 0.85 | NOS2 (0.35) | NOS2NOS3HCRTR2 | |
| SCHEMBL31214428 | 0.78 | NOS2 (0.33) | NOS2NOS3 | |
| SCHEMBL31214396 | 0.76 | HCRTR2 (0.32) | NOS2NOS3HCRTR2 | |
| SCHEMBL31214442 | 0.74 | HCRTR2 (0.42) | FFAR4HCRTR2 | |
| SCHEMBL31214520 | 0.72 | NOS2 (0.38) | NOS2NOS3ABL1 | |
| SCHEMBL31214381 | 0.71 | NOS2 (0.34) | NOS2NOS3 | |
| SCHEMBL305502 | 0.70 | NOS2 (0.45) | NOS2NOS3 | |
| SCHEMBL31150926 | 0.70 | NOS2 (0.45) | NOS2NOS3 | |
| SCHEMBL31214347 | 0.70 | NOS2 (0.36) | NOS2NOS3 | |
| SCHEMBL31214517 | 0.70 | OPRL1 (0.38) | NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| WO-2024211744-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | GRIN2C, HCN1, KCNC1 | NOS2 3832/4885NOS3 2918/4885FFAR4 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.